

JUL 30 2003

510(k) Summary - Elecsys® PreciControl Cardiac

K032089

Introduction According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence

Submitter name, address, contact Roche Diagnostics Corporation
9115 Hague Rd
Indianapolis IN 46250
(317) 521-3831

Contact person: Sherri L. Coenen

Date prepared: July 2, 2003

Device Name Proprietary name: Roche Diagnostics Elecsys® PreciControl Cardiac

Common name: Elecsys® PreciControl Cardiac

Classification name: Multi-analyte Controls (assayed and unassayed)

Device description Roche Diagnostics Elecsys® PreciControl Cardiac is a bilevel lyophilized preparation of pooled human sera containing CK-MB, Digoxin, Myoglobin, and NT-proBNP for monitoring accuracy and precision on Elecsys immunoassay analyzers.

Intended use PreciControl Cardiac is used for quality control of the Elecsys CK-MB, Digoxin, Myoglobin, and NT-proBNP immunoassays on the Elecsys immunoassay systems.

Predicate Device We claim substantial equivalence to the currently marketed Elecsys® PreciControl Cardiac. (K983492).

510(k) Summary - COBAS Integra Creatinine plus ver.2, continued

Reagent Summary The following table describes the similarities and differences between the Elecsys® PreciControl Cardiac and the predicate device.

Topic	Elecsys® PreciControl Cardiac (K983492)	Elecsys® PreciControl Cardiac (Modified Device)
Intended Use	PreciControl Cardiac is used for quality control of the Elecsys CK-MB, Myoglobin and Troponin T (CARDIAC T) immunoassays on Elecsys immunoassay systems.	PreciControl Cardiac is used for quality control of the Elecsys CK-MB, Digoxin, Myoglobin, and NT-proBNP immunoassays on the Elecsys immunoassay systems.
Analyzer System	Elecsys® immunoassay analyzers	Same
Reagent Format	lyophilized, based on human serum	Same
Analyte Concentration PC CARD 1	CK-MB: approximately 5 ng/ml Myoglobin: approximately 80 ng/ml Troponin T: approximately 0.15 ng/ml	CK-MB: Same Myoglobin: Same Digoxin: approximately 1.2 ng/ml NT-proBNP: approximately 0.15 ng/ml
Analyte Concentration PC CARD 2	CK-MB: approximately 50 ng/ml Myoglobin: approximately 1000 ng/ml Troponin T: approximately 5 ng/ml	CK-MB: Same Myoglobin: Same Digoxin: approximately 3 ng/ml NT-proBNP: approximately 5 ng/ml
Stability	3 hrs at 20 - 25° C 3 days at 2 - 8° C 3 months at -20° C (only freeze once)	Same



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

JUL 30 2003

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

Ms. Sherri L. Coenen MT(ASCP)
Regulatory Affairs Consultant
Regulatory Submissions, Centralized Diagnostics
Roche Diagnostics Corporation
9115 Hague Road
P.O. Box 50457
Indianapolis, IN 46250-0457

Re: k032089
Trade/Device Name: Elecsys® PreciControl Cardiac
Regulation Number: 21 CFR 862.1660
Regulation Name: Quality control material (assayed and unassayed)
Regulatory Class: Class I
Product Code: JJY
Dated: July 2, 2003
Received: July 7, 2003

Dear Ms. Coenen:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 –

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive, slightly slanted style.

Steven I. Gutman, M.D., M.B.A.
Director
Office of *In Vitro* Diagnostic Device
Evaluation and Safety
Center for Devices and
Radiological Health

Enclosure


Indications for Use Statement

510(k) Number (if known): N/A K032089

Device Name: Elecsys® PreciControl Cardiac

Indications For Use:

PreciControl Cardiac is used for quality control of the Elecsys CK-MB, Digoxin, Myoglobin, and NT-proBNP immunoassays on the Elecsys immunoassay systems.


Division Sign-Off

Office of In Vitro Diagnostic Device
Evaluation and Safety

510(k) K032089

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF
NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use X OR Over-The-Counter Use _____
(Per 21 CFR 801.109)

(Optional Format 1-2-96)